<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443403</url>
  </required_header>
  <id_info>
    <org_study_id>1107V9221</org_study_id>
    <nct_id>NCT01443403</nct_id>
  </id_info>
  <brief_title>A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy and safety of naldemedine for the
      treatment of opioid-induced constipation in adults with non-malignant chronic pain receiving
      opioid therapy for â‰¥ 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2011</start_date>
  <completion_date type="Actual">August 22, 2012</completion_date>
  <primary_completion_date type="Actual">August 22, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week</measure>
    <time_frame>Baseline (2 weeks prior to randomization) and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A spontaneous bowel movement was defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per week during the 2 weeks prior to randomization. The number of SBMs per week in the last 2 weeks of treatment is defined as the average number of SBMs per week recorded in the diary for the 14 days prior to the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Spontaneous Bowel Movements Per Week</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A spontaneous bowel movement was defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per day during the 2 weeks prior to randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Bowel Movements (BMs) Per Week</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A BM was defined as all bowel movements observed irrespective of the use of a laxative agent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Bowel Movements Per Week</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A BM was defined as all bowel movements observed irrespective of the use of a laxative agent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Bowel Movements (CBMs) Per Week</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A complete BM (CBM) was defined as a BM where the participant answered 'Yes' to the following question: 'Did you have a feeling of complete emptying after the bowel movement?'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Bowel Movements Per Week</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A complete BM (CBM) was defined as a BM where the participant answered 'Yes' to the following question: 'Did you have a feeling of complete emptying after the bowel movement?'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Spontaneous Bowel Movements Per Week</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an SBM Response in the Last 2 Weeks of the Treatment Period</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM responder was defined as a participant whose frequency of SBMs within the last 2 weeks of the treatment period was 3 times or more per week and who had an average increase in the frequency of SBMs from baseline of 1 or more per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an SBM Response at Weeks 1, 2, 3 and 4</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM responder was defined as any participant whose frequency of SBM per week during the treatment period was 3 times or more per week, and who had an average increase from baseline of 1 or more per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a CSBM Response in the Last 2 Weeks of the Treatment Period</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM responder was defined as a participant whose frequency of CSBMs within the last 2 weeks of the treatment period was 3 times or more per week and who had an average increase in the frequency of CSBMs from baseline of 1 or more per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a CSBM Response at Weeks 1, 2, 3, and 4</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM responder was defined as a participant whose frequency of CSBMs during the treatment period was 3 times or more per week and who had an average increase in the frequency of CSBMs from baseline of 1 or more per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With SBMs</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM is defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With SBMs</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM is defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With CSBMs</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With CSBMs</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Spontaneous Bowel Movement</measure>
    <time_frame>28 days</time_frame>
    <description>Time to the first SBM was defined as the time to the first SBM after the initial administration of study drug. Participants who withdrew from the study before an SBM was observed or had no SBM during the treatment period were treated as censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Complete Spontaneous Bowel Movement</measure>
    <time_frame>28 days</time_frame>
    <description>Time to the first CSBM was defined as the time to the first CSBM after the initial administration of study drug. Participants who withdrew from the study before a CSBM was observed or had no CSBM during the treatment period were treated as censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug</measure>
    <time_frame>4, 8, 12, and 24 hours</time_frame>
    <description>The percentage of participants who experienced at least one SBM within 4, 8, 12, and 24 hours after the initial administration of study drug and before the second administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CSBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug</measure>
    <time_frame>4, 8, 12, and 24 hours</time_frame>
    <description>The percentage of participants who experienced at least one CSBM within 4, 8, 12, and 24 hours after the initial administration of study drug and before the second administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week Rated as 3 or 4 on the Bristol Stool Scale</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Consistency of BMs was measured using the Bristol Stool Scale, according to the following: 1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3, and 4 in Number of SBMs Rated as 3 or 4 on the Bristol Stool Scale Per Week</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Consistency of BMs was measured using the Bristol Stool Scale, according to the following: 1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week With no Straining</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Straining during BMs was graded using the following scale: 0 = No straining; 1 = Mild straining; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining was defined as a BM with a straining score of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of SBMs Per Week Without Straining</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Straining during BMs was graded using the following scale: 0 = No straining; 1 = Mild straining; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining is defined as a BM with a straining score of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of False Start BMs Per Week</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A false start was defined as any attempted, but unsuccessful bowel movement (no solid or liquid fecal material was excreted).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in Rescue Use of Laxative Agents Per Week</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants were asked how many doses of rescue laxative medication they had taken within the past 24 hours as part of the Bowel Movement and Constipation Assessment Diary (BMCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rescue Laxative Use Per Week During the Treatment Period</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>Participants were asked how many doses of rescue laxative medication they had taken within the past 24 hours as part of the Bowel Movement and Constipation Assessment Diary (BMCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Bloating</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants were asked to rate their abdominal bloating for the past 24 hours on a scale of 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Bloating</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants were asked to rate their abdominal bloating for the past 24 hours on a scale of 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Discomfort</measure>
    <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
    <description>Participants were asked to rate their abdominal discomfort for the past 24 hours on a scale from 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Discomfort</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
    <description>Participants were asked to rate their abdominal discomfort for the past 24 hours on a scale from 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Satisfaction at End of Treatment</measure>
    <time_frame>Day 29, or at early termination</time_frame>
    <description>On day 29 (or at early termination), participants were asked about their degree of satisfaction with constipation and abdominal symptoms from the start of study drug dosing to Day 28 (or early termination visit). The grades were as follows: 1, markedly worsened; 2, moderately worsened; 3, slightly worsened; 4, unchanged; 5, slightly improved; 6, moderately improved; and 7, markedly improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995</measure>
    <time_frame>Day 1 and Day 28 predose and 1, 2, 4, 8, and 24 hours postdose</time_frame>
    <description>Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of Naldemedine and Metabolite Nor-S-297995</measure>
    <time_frame>Day 1 and Day 28 predose and 1, 2 , 4, 8, and 24 hours postdose</time_frame>
    <description>Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Hour 0 to the Time Point of the Last Measurable Concentration Within the Dose Interval (AUC0-Ï„)</measure>
    <time_frame>Day 1 and Day 28 predose and 1, 2 , 4, 8, and 24 hours postdose</time_frame>
    <description>Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From first dose of study drug through 28 days after the last dose of study treatment (up to 57 days).</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) were adverse events that occurred after the first dose of study drug.
Treatment-related TEAEs were defined as TEAEs that were considered by the Investigator to be definitely, probably, or possibly related to study drug.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Opioid-induced Constipation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo orally once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naldemedine 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naldemedine 0.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naldemedine 0.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets administered orally once a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naldemedine</intervention_name>
    <description>Naldemedine tablets administered orally once a day.</description>
    <arm_group_label>Naldemedine 0.4 mg</arm_group_label>
    <arm_group_label>Naldemedine 0.1 mg</arm_group_label>
    <arm_group_label>Naldemedine 0.2 mg</arm_group_label>
    <other_name>S 297995</other_name>
    <other_name>SymproicÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 years or older at time of informed consent with non-malignant chronic
             pain experiencing opioid-induced constipation

          -  Subjects with &lt; 3 spontaneous bowel movements a week and experiencing bowel symptoms

          -  Subjects receiving chronic opioid therapy due to non-malignant pain for â‰¥ 3 months

        Exclusion Criteria:

          -  Evidence of clinically significant gastrointestinal disease

          -  History of chronic constipation prior to starting analgesic medication or any
             potential non-opioid cause of bowel dysfunction that may be a major contributor to the
             constipation

          -  Severe constipation that has not been appropriately managed such that the subject is
             at immediate risk of developing serious complications of constipation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Sun Lakes</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Newington</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>North Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shionogi Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Webster LR, Yamada T, Arjona Ferreira JC. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Med. 2017 Dec 1;18(12):2350-2360. doi: 10.1093/pm/pnw325.</citation>
    <PMID>28371937</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <results_first_submitted>April 19, 2017</results_first_submitted>
  <results_first_submitted_qc>April 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid Therapy</keyword>
  <keyword>Non-Malignant Chronic Pain</keyword>
  <keyword>Opioid-Induced Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 53 clinical sites in the United States. The first participant was enrolled on August 17, 2011 and the last participant completed on August 22, 2012.
Participants must have met eligibility criteria and completed the Bowel Movement and Constipation Assessment (BMCA) Diary for a minimum of 14 days to enroll in the study.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 1:1:1:1 ratio to receive placebo, naldemedine 0.1 mg, 0.2 mg, or 0.4 mg once daily.
One participant was randomized twice, first to placebo and subsequently to naldemedine 0.4 mg, and is counted in both arms below and for safety analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo orally once daily for 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Naldemedine 0.1 mg</title>
          <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
        </group>
        <group group_id="P3">
          <title>Naldemedine 0.2 mg</title>
          <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
        </group>
        <group group_id="P4">
          <title>Naldemedine 0.4 mg</title>
          <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of Prohibited Treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The modified intention-to-treat (mITT) population included all randomized participants who received study drug and had at least 1 postdose primary efficacy assessment completed. One participant who randomized twice was excluded from the naldemedine 0.4 mg arm for the mITT population.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo orally once daily for 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Naldemedine 0.1 mg</title>
          <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Naldemedine 0.2 mg</title>
          <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Naldemedine 0.4 mg</title>
          <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="59"/>
            <count group_id="B4" value="57"/>
            <count group_id="B5" value="238"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="10.88"/>
                    <measurement group_id="B2" value="49.5" spread="9.71"/>
                    <measurement group_id="B3" value="50.7" spread="11.40"/>
                    <measurement group_id="B4" value="54.1" spread="11.19"/>
                    <measurement group_id="B5" value="51.9" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>â‰¥ 18 - &lt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 40 - &lt; 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 50 - &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 65 - &lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spontaneous Bowel Movement (SBM) Frequency per Week</title>
          <units>SBMs/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.22" spread="0.720"/>
                    <measurement group_id="B2" value="1.51" spread="0.820"/>
                    <measurement group_id="B3" value="1.52" spread="0.916"/>
                    <measurement group_id="B4" value="1.20" spread="0.948"/>
                    <measurement group_id="B5" value="1.36" spread="0.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A spontaneous bowel movement was defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per week during the 2 weeks prior to randomization. The number of SBMs per week in the last 2 weeks of treatment is defined as the average number of SBMs per week recorded in the diary for the 14 days prior to the last dose of study drug.</description>
        <time_frame>Baseline (2 weeks prior to randomization) and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>Modified intention-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A spontaneous bowel movement was defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per week during the 2 weeks prior to randomization. The number of SBMs per week in the last 2 weeks of treatment is defined as the average number of SBMs per week recorded in the diary for the 14 days prior to the last dose of study drug.</description>
          <population>Modified intention-to-treat population</population>
          <units>spontaneous bowel movements per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.422"/>
                    <measurement group_id="O2" value="1.98" spread="0.422"/>
                    <measurement group_id="O3" value="3.37" spread="0.429"/>
                    <measurement group_id="O4" value="3.64" spread="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.605</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.604</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>3.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3504</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.599</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Spontaneous Bowel Movements Per Week</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A spontaneous bowel movement was defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per day during the 2 weeks prior to randomization.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with values at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Spontaneous Bowel Movements Per Week</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A spontaneous bowel movement was defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per day during the 2 weeks prior to randomization.</description>
          <population>mITT population with values at both baseline and the specified time point.</population>
          <units>spontaneous bowel movements per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.507"/>
                    <measurement group_id="O2" value="2.21" spread="0.507"/>
                    <measurement group_id="O3" value="4.05" spread="0.516"/>
                    <measurement group_id="O4" value="4.52" spread="0.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 60, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.402"/>
                    <measurement group_id="O2" value="2.06" spread="0.402"/>
                    <measurement group_id="O3" value="2.99" spread="0.410"/>
                    <measurement group_id="O4" value="3.87" spread="0.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.374"/>
                    <measurement group_id="O2" value="2.27" spread="0.372"/>
                    <measurement group_id="O3" value="3.07" spread="0.380"/>
                    <measurement group_id="O4" value="3.33" spread="0.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.409"/>
                    <measurement group_id="O2" value="1.69" spread="0.409"/>
                    <measurement group_id="O3" value="3.30" spread="0.415"/>
                    <measurement group_id="O4" value="3.41" spread="0.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Bowel Movements (BMs) Per Week</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A BM was defined as all bowel movements observed irrespective of the use of a laxative agent.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Bowel Movements (BMs) Per Week</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A BM was defined as all bowel movements observed irrespective of the use of a laxative agent.</description>
          <population>mITT population</population>
          <units>bowel movements per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.396"/>
                    <measurement group_id="O2" value="2.07" spread="0.394"/>
                    <measurement group_id="O3" value="3.35" spread="0.404"/>
                    <measurement group_id="O4" value="3.36" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.568</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.569</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>3.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2572</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.558</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Bowel Movements Per Week</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A BM was defined as all bowel movements observed irrespective of the use of a laxative agent.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with values at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Bowel Movements Per Week</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A BM was defined as all bowel movements observed irrespective of the use of a laxative agent.</description>
          <population>mITT population with values at both baseline and the specified time point.</population>
          <units>bowel movements per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.457"/>
                    <measurement group_id="O2" value="2.27" spread="0.456"/>
                    <measurement group_id="O3" value="4.25" spread="0.466"/>
                    <measurement group_id="O4" value="4.60" spread="0.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 60, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.361"/>
                    <measurement group_id="O2" value="1.97" spread="0.360"/>
                    <measurement group_id="O3" value="2.96" spread="0.369"/>
                    <measurement group_id="O4" value="3.75" spread="0.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.347"/>
                    <measurement group_id="O2" value="2.36" spread="0.344"/>
                    <measurement group_id="O3" value="3.02" spread="0.352"/>
                    <measurement group_id="O4" value="2.93" spread="0.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.373"/>
                    <measurement group_id="O2" value="1.68" spread="0.372"/>
                    <measurement group_id="O3" value="3.06" spread="0.379"/>
                    <measurement group_id="O4" value="3.16" spread="0.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Bowel Movements (CBMs) Per Week</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A complete BM (CBM) was defined as a BM where the participant answered â€˜Yesâ€™ to the following question: â€˜Did you have a feeling of complete emptying after the bowel movement?â€™</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Bowel Movements (CBMs) Per Week</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A complete BM (CBM) was defined as a BM where the participant answered â€˜Yesâ€™ to the following question: â€˜Did you have a feeling of complete emptying after the bowel movement?â€™</description>
          <population>mITT population</population>
          <units>complete bowel movements per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.336"/>
                    <measurement group_id="O2" value="1.58" spread="0.336"/>
                    <measurement group_id="O3" value="2.71" spread="0.344"/>
                    <measurement group_id="O4" value="2.41" spread="0.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0065</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.484</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.482</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2921</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.476</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Bowel Movements Per Week</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A complete BM (CBM) was defined as a BM where the participant answered â€˜Yesâ€™ to the following question: â€˜Did you have a feeling of complete emptying after the bowel movement?â€™</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with values at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Bowel Movements Per Week</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A complete BM (CBM) was defined as a BM where the participant answered â€˜Yesâ€™ to the following question: â€˜Did you have a feeling of complete emptying after the bowel movement?â€™</description>
          <population>mITT population with values at both baseline and the specified time point.</population>
          <units>complete bowel movements per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.381"/>
                    <measurement group_id="O2" value="1.38" spread="0.380"/>
                    <measurement group_id="O3" value="2.88" spread="0.388"/>
                    <measurement group_id="O4" value="3.14" spread="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 60, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.324"/>
                    <measurement group_id="O2" value="1.54" spread="0.324"/>
                    <measurement group_id="O3" value="1.99" spread="0.331"/>
                    <measurement group_id="O4" value="2.50" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.297"/>
                    <measurement group_id="O2" value="1.62" spread="0.296"/>
                    <measurement group_id="O3" value="2.29" spread="0.302"/>
                    <measurement group_id="O4" value="2.12" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.334"/>
                    <measurement group_id="O2" value="1.60" spread="0.333"/>
                    <measurement group_id="O3" value="2.77" spread="0.339"/>
                    <measurement group_id="O4" value="2.56" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
          <population>mITT population</population>
          <units>complete spontaneous BMs per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.345"/>
                    <measurement group_id="O2" value="1.49" spread="0.344"/>
                    <measurement group_id="O3" value="2.69" spread="0.351"/>
                    <measurement group_id="O4" value="2.44" spread="0.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0039</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.495</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.492</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3077</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.488</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Spontaneous Bowel Movements Per Week</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with values at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Spontaneous Bowel Movements Per Week</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
          <population>mITT population with values at both baseline and the specified time point.</population>
          <units>complete spontaneous BMs per week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.386"/>
                    <measurement group_id="O2" value="1.31" spread="0.386"/>
                    <measurement group_id="O3" value="2.63" spread="0.393"/>
                    <measurement group_id="O4" value="2.99" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 60, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.326"/>
                    <measurement group_id="O2" value="1.41" spread="0.326"/>
                    <measurement group_id="O3" value="2.08" spread="0.332"/>
                    <measurement group_id="O4" value="2.50" spread="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.303"/>
                    <measurement group_id="O2" value="1.53" spread="0.301"/>
                    <measurement group_id="O3" value="2.28" spread="0.307"/>
                    <measurement group_id="O4" value="2.21" spread="0.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.340"/>
                    <measurement group_id="O2" value="1.51" spread="0.340"/>
                    <measurement group_id="O3" value="2.77" spread="0.345"/>
                    <measurement group_id="O4" value="2.58" spread="0.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an SBM Response in the Last 2 Weeks of the Treatment Period</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM responder was defined as a participant whose frequency of SBMs within the last 2 weeks of the treatment period was 3 times or more per week and who had an average increase in the frequency of SBMs from baseline of 1 or more per week.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an SBM Response in the Last 2 Weeks of the Treatment Period</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM responder was defined as a participant whose frequency of SBMs within the last 2 weeks of the treatment period was 3 times or more per week and who had an average increase in the frequency of SBMs from baseline of 1 or more per week.</description>
          <population>mITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3"/>
                    <measurement group_id="O2" value="52.5"/>
                    <measurement group_id="O3" value="71.2"/>
                    <measurement group_id="O4" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Chi-squared</method>
            <param_type>Difference</param_type>
            <param_value>27.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.0</ci_lower_limit>
            <ci_upper_limit>44.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Chi-squared</method>
            <param_type>Difference</param_type>
            <param_value>31.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.0</ci_lower_limit>
            <ci_upper_limit>48.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1461</p_value>
            <method>Chi-squared</method>
            <param_type>Difference</param_type>
            <param_value>13.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>30.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an SBM Response at Weeks 1, 2, 3 and 4</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM responder was defined as any participant whose frequency of SBM per week during the treatment period was 3 times or more per week, and who had an average increase from baseline of 1 or more per week.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population; missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an SBM Response at Weeks 1, 2, 3 and 4</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM responder was defined as any participant whose frequency of SBM per week during the treatment period was 3 times or more per week, and who had an average increase from baseline of 1 or more per week.</description>
          <population>mITT population; missing data were imputed using last observation carried forward (LOCF).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                    <measurement group_id="O2" value="62.3"/>
                    <measurement group_id="O3" value="72.9"/>
                    <measurement group_id="O4" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                    <measurement group_id="O2" value="55.7"/>
                    <measurement group_id="O3" value="69.5"/>
                    <measurement group_id="O4" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                    <measurement group_id="O2" value="55.7"/>
                    <measurement group_id="O3" value="74.6"/>
                    <measurement group_id="O4" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3"/>
                    <measurement group_id="O2" value="42.6"/>
                    <measurement group_id="O3" value="64.4"/>
                    <measurement group_id="O4" value="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a CSBM Response in the Last 2 Weeks of the Treatment Period</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM responder was defined as a participant whose frequency of CSBMs within the last 2 weeks of the treatment period was 3 times or more per week and who had an average increase in the frequency of CSBMs from baseline of 1 or more per week.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a CSBM Response in the Last 2 Weeks of the Treatment Period</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM responder was defined as a participant whose frequency of CSBMs within the last 2 weeks of the treatment period was 3 times or more per week and who had an average increase in the frequency of CSBMs from baseline of 1 or more per week.</description>
          <population>mITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="29.5"/>
                    <measurement group_id="O3" value="45.8"/>
                    <measurement group_id="O4" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0050</p_value>
            <method>Chi-squared</method>
            <param_type>Difference</param_type>
            <param_value>24.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.8</ci_lower_limit>
            <ci_upper_limit>40.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <method>Chi-squared</method>
            <param_type>Difference</param_type>
            <param_value>24.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.1</ci_lower_limit>
            <ci_upper_limit>40.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2984</p_value>
            <method>Chi-squared</method>
            <param_type>Difference</param_type>
            <param_value>8.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>23.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a CSBM Response at Weeks 1, 2, 3, and 4</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM responder was defined as a participant whose frequency of CSBMs during the treatment period was 3 times or more per week and who had an average increase in the frequency of CSBMs from baseline of 1 or more per week.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population; missing data were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a CSBM Response at Weeks 1, 2, 3, and 4</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM responder was defined as a participant whose frequency of CSBMs during the treatment period was 3 times or more per week and who had an average increase in the frequency of CSBMs from baseline of 1 or more per week.</description>
          <population>mITT population; missing data were imputed using last observation carried forward (LOCF).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="42.4"/>
                    <measurement group_id="O4" value="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="29.5"/>
                    <measurement group_id="O3" value="42.4"/>
                    <measurement group_id="O4" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="37.7"/>
                    <measurement group_id="O3" value="44.1"/>
                    <measurement group_id="O4" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="45.8"/>
                    <measurement group_id="O4" value="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With SBMs</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM is defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With SBMs</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM is defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement.</description>
          <population>mITT population</population>
          <units>days/week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.223"/>
                    <measurement group_id="O2" value="1.46" spread="0.223"/>
                    <measurement group_id="O3" value="2.10" spread="0.227"/>
                    <measurement group_id="O4" value="2.42" spread="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.320</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.320</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0698</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.317</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With SBMs</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM is defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with values at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With SBMs</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
An SBM is defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement.</description>
          <population>mITT population with values at both baseline and the specified time point.</population>
          <units>days/week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.250"/>
                    <measurement group_id="O2" value="1.62" spread="0.251"/>
                    <measurement group_id="O3" value="2.35" spread="0.255"/>
                    <measurement group_id="O4" value="2.38" spread="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 60, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.240"/>
                    <measurement group_id="O2" value="1.56" spread="0.240"/>
                    <measurement group_id="O3" value="2.03" spread="0.245"/>
                    <measurement group_id="O4" value="2.45" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.233"/>
                    <measurement group_id="O2" value="1.57" spread="0.232"/>
                    <measurement group_id="O3" value="2.07" spread="0.237"/>
                    <measurement group_id="O4" value="2.37" spread="0.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.274"/>
                    <measurement group_id="O2" value="1.27" spread="0.274"/>
                    <measurement group_id="O3" value="2.20" spread="0.278"/>
                    <measurement group_id="O4" value="2.52" spread="0.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With CSBMs</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With CSBMs</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
          <population>mITT population</population>
          <units>days/week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.214"/>
                    <measurement group_id="O2" value="1.25" spread="0.213"/>
                    <measurement group_id="O3" value="1.93" spread="0.217"/>
                    <measurement group_id="O4" value="2.02" spread="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.307</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.305</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1648</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.302</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With CSBMs</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with values at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With CSBMs</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.</description>
          <population>mITT population with values at both baseline and the specified time point.</population>
          <units>days/week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.234"/>
                    <measurement group_id="O2" value="1.17" spread="0.234"/>
                    <measurement group_id="O3" value="1.74" spread="0.238"/>
                    <measurement group_id="O4" value="2.14" spread="0.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 60, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.226"/>
                    <measurement group_id="O2" value="1.18" spread="0.226"/>
                    <measurement group_id="O3" value="1.65" spread="0.230"/>
                    <measurement group_id="O4" value="1.93" spread="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.224"/>
                    <measurement group_id="O2" value="1.26" spread="0.223"/>
                    <measurement group_id="O3" value="1.71" spread="0.228"/>
                    <measurement group_id="O4" value="1.98" spread="0.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.256"/>
                    <measurement group_id="O2" value="1.31" spread="0.256"/>
                    <measurement group_id="O3" value="2.17" spread="0.260"/>
                    <measurement group_id="O4" value="2.10" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Spontaneous Bowel Movement</title>
        <description>Time to the first SBM was defined as the time to the first SBM after the initial administration of study drug. Participants who withdrew from the study before an SBM was observed or had no SBM during the treatment period were treated as censored.</description>
        <time_frame>28 days</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Spontaneous Bowel Movement</title>
          <description>Time to the first SBM was defined as the time to the first SBM after the initial administration of study drug. Participants who withdrew from the study before an SBM was observed or had no SBM during the treatment period were treated as censored.</description>
          <population>mITT population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.57" lower_limit="34.70" upper_limit="71.25"/>
                    <measurement group_id="O2" value="28.15" lower_limit="15.75" upper_limit="45.02"/>
                    <measurement group_id="O3" value="11.08" lower_limit="4.15" upper_limit="25.25"/>
                    <measurement group_id="O4" value="21.33" lower_limit="4.67" upper_limit="26.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0118</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Complete Spontaneous Bowel Movement</title>
        <description>Time to the first CSBM was defined as the time to the first CSBM after the initial administration of study drug. Participants who withdrew from the study before a CSBM was observed or had no CSBM during the treatment period were treated as censored.</description>
        <time_frame>28 days</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Complete Spontaneous Bowel Movement</title>
          <description>Time to the first CSBM was defined as the time to the first CSBM after the initial administration of study drug. Participants who withdrew from the study before a CSBM was observed or had no CSBM during the treatment period were treated as censored.</description>
          <population>mITT population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.92" lower_limit="101.25" upper_limit="350.40"/>
                    <measurement group_id="O2" value="82.50" lower_limit="49.30" upper_limit="140.40"/>
                    <measurement group_id="O3" value="44.83" lower_limit="25.58" upper_limit="107.17"/>
                    <measurement group_id="O4" value="32.93" lower_limit="18.00" upper_limit="55.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug</title>
        <description>The percentage of participants who experienced at least one SBM within 4, 8, 12, and 24 hours after the initial administration of study drug and before the second administration.</description>
        <time_frame>4, 8, 12, and 24 hours</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug</title>
          <description>The percentage of participants who experienced at least one SBM within 4, 8, 12, and 24 hours after the initial administration of study drug and before the second administration.</description>
          <population>mITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="18.0"/>
                    <measurement group_id="O3" value="35.6"/>
                    <measurement group_id="O4" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="29.5"/>
                    <measurement group_id="O3" value="47.5"/>
                    <measurement group_id="O4" value="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0"/>
                    <measurement group_id="O2" value="34.4"/>
                    <measurement group_id="O3" value="50.8"/>
                    <measurement group_id="O4" value="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="44.3"/>
                    <measurement group_id="O3" value="59.3"/>
                    <measurement group_id="O4" value="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CSBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug</title>
        <description>The percentage of participants who experienced at least one CSBM within 4, 8, 12, and 24 hours after the initial administration of study drug and before the second administration.</description>
        <time_frame>4, 8, 12, and 24 hours</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CSBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug</title>
          <description>The percentage of participants who experienced at least one CSBM within 4, 8, 12, and 24 hours after the initial administration of study drug and before the second administration.</description>
          <population>mITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="11.5"/>
                    <measurement group_id="O3" value="18.6"/>
                    <measurement group_id="O4" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="16.4"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="21.3"/>
                    <measurement group_id="O3" value="23.7"/>
                    <measurement group_id="O4" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Up to 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="27.9"/>
                    <measurement group_id="O3" value="30.5"/>
                    <measurement group_id="O4" value="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week Rated as 3 or 4 on the Bristol Stool Scale</title>
        <description>Consistency of BMs was measured using the Bristol Stool Scale, according to the following: 1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week Rated as 3 or 4 on the Bristol Stool Scale</title>
          <description>Consistency of BMs was measured using the Bristol Stool Scale, according to the following: 1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.</description>
          <population>mITT population</population>
          <units>spontaneous bowel movements/week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.249"/>
                    <measurement group_id="O2" value="1.08" spread="0.249"/>
                    <measurement group_id="O3" value="2.05" spread="0.256"/>
                    <measurement group_id="O4" value="1.87" spread="0.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.358</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.359</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1211</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.352</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3, and 4 in Number of SBMs Rated as 3 or 4 on the Bristol Stool Scale Per Week</title>
        <description>Consistency of BMs was measured using the Bristol Stool Scale, according to the following: 1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with values at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3, and 4 in Number of SBMs Rated as 3 or 4 on the Bristol Stool Scale Per Week</title>
          <description>Consistency of BMs was measured using the Bristol Stool Scale, according to the following: 1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.</description>
          <population>mITT population with values at both baseline and the specified time point.</population>
          <units>spontaneous bowel movements/week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.278"/>
                    <measurement group_id="O2" value="0.97" spread="0.278"/>
                    <measurement group_id="O3" value="2.16" spread="0.285"/>
                    <measurement group_id="O4" value="1.76" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 60, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.271"/>
                    <measurement group_id="O2" value="1.19" spread="0.270"/>
                    <measurement group_id="O3" value="2.03" spread="0.278"/>
                    <measurement group_id="O4" value="1.98" spread="0.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.262"/>
                    <measurement group_id="O2" value="1.08" spread="0.261"/>
                    <measurement group_id="O3" value="2.03" spread="0.268"/>
                    <measurement group_id="O4" value="1.91" spread="0.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.307"/>
                    <measurement group_id="O2" value="1.10" spread="0.307"/>
                    <measurement group_id="O3" value="2.01" spread="0.313"/>
                    <measurement group_id="O4" value="1.94" spread="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week With no Straining</title>
        <description>Straining during BMs was graded using the following scale: 0 = No straining; 1 = Mild straining; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining was defined as a BM with a straining score of 0 or 1.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week With no Straining</title>
          <description>Straining during BMs was graded using the following scale: 0 = No straining; 1 = Mild straining; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining was defined as a BM with a straining score of 0 or 1.</description>
          <population>mITT population</population>
          <units>bowel movements/week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.384"/>
                    <measurement group_id="O2" value="1.54" spread="0.383"/>
                    <measurement group_id="O3" value="2.92" spread="0.391"/>
                    <measurement group_id="O4" value="3.21" spread="0.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.551</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>3.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.549</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>3.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2022</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a term and baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.542</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of SBMs Per Week Without Straining</title>
        <description>Straining during BMs was graded using the following scale: 0 = No straining; 1 = Mild straining; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining is defined as a BM with a straining score of 0 or 1.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with values at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of SBMs Per Week Without Straining</title>
          <description>Straining during BMs was graded using the following scale: 0 = No straining; 1 = Mild straining; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining is defined as a BM with a straining score of 0 or 1.</description>
          <population>mITT population with values at both baseline and the specified time point.</population>
          <units>bowel movements/week</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.443"/>
                    <measurement group_id="O2" value="1.42" spread="0.442"/>
                    <measurement group_id="O3" value="3.23" spread="0.451"/>
                    <measurement group_id="O4" value="3.46" spread="0.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 60, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.382"/>
                    <measurement group_id="O2" value="1.43" spread="0.382"/>
                    <measurement group_id="O3" value="2.54" spread="0.390"/>
                    <measurement group_id="O4" value="3.27" spread="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.371"/>
                    <measurement group_id="O2" value="1.70" spread="0.369"/>
                    <measurement group_id="O3" value="2.67" spread="0.377"/>
                    <measurement group_id="O4" value="3.06" spread="0.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 60, 60, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.359"/>
                    <measurement group_id="O2" value="1.39" spread="0.358"/>
                    <measurement group_id="O3" value="2.82" spread="0.365"/>
                    <measurement group_id="O4" value="2.84" spread="0.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of False Start BMs Per Week</title>
        <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A false start was defined as any attempted, but unsuccessful bowel movement (no solid or liquid fecal material was excreted).</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population with values at both baseline and the last 2 weeks of the treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of False Start BMs Per Week</title>
          <description>Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.
A false start was defined as any attempted, but unsuccessful bowel movement (no solid or liquid fecal material was excreted).</description>
          <population>mITT population with values at both baseline and the last 2 weeks of the treatment period</population>
          <units>false start BMs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="5.105"/>
                    <measurement group_id="O2" value="-3.06" spread="4.568"/>
                    <measurement group_id="O3" value="-3.75" spread="5.673"/>
                    <measurement group_id="O4" value="-2.80" spread="5.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Rescue Use of Laxative Agents Per Week</title>
        <description>Participants were asked how many doses of rescue laxative medication they had taken within the past 24 hours as part of the Bowel Movement and Constipation Assessment Diary (BMCA).</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Rescue Use of Laxative Agents Per Week</title>
          <description>Participants were asked how many doses of rescue laxative medication they had taken within the past 24 hours as part of the Bowel Movement and Constipation Assessment Diary (BMCA).</description>
          <population>mITT population</population>
          <units>doses/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="6.068"/>
                    <measurement group_id="O2" value="-0.47" spread="1.691"/>
                    <measurement group_id="O3" value="0.15" spread="07.211"/>
                    <measurement group_id="O4" value="-1.24" spread="2.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0272</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1355</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3689</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rescue Laxative Use Per Week During the Treatment Period</title>
        <description>Participants were asked how many doses of rescue laxative medication they had taken within the past 24 hours as part of the Bowel Movement and Constipation Assessment Diary (BMCA).</description>
        <time_frame>Weeks 1 to 4</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rescue Laxative Use Per Week During the Treatment Period</title>
          <description>Participants were asked how many doses of rescue laxative medication they had taken within the past 24 hours as part of the Bowel Movement and Constipation Assessment Diary (BMCA).</description>
          <population>mITT population</population>
          <units>doses/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="6.98"/>
                    <measurement group_id="O2" value="0.9" spread="1.81"/>
                    <measurement group_id="O3" value="2.9" spread="7.64"/>
                    <measurement group_id="O4" value="1.8" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Bloating</title>
        <description>Participants were asked to rate their abdominal bloating for the past 24 hours on a scale of 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population with a value at both baseline and the last 2 weeks of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Bloating</title>
          <description>Participants were asked to rate their abdominal bloating for the past 24 hours on a scale of 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
          <population>mITT population with a value at both baseline and the last 2 weeks of treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.689"/>
                    <measurement group_id="O2" value="-0.46" spread="0.759"/>
                    <measurement group_id="O3" value="-0.54" spread="0.719"/>
                    <measurement group_id="O4" value="-0.57" spread="0.773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2126</p_value>
            <method>Welchâ€™s t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2799</p_value>
            <method>Welchâ€™s t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6466</p_value>
            <method>Welchâ€™s t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Bloating</title>
        <description>Participants were asked to rate their abdominal bloating for the past 24 hours on a scale of 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with a value at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Bloating</title>
          <description>Participants were asked to rate their abdominal bloating for the past 24 hours on a scale of 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
          <population>mITT population with a value at both baseline and the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.592"/>
                    <measurement group_id="O2" value="-0.30" spread="0.621"/>
                    <measurement group_id="O3" value="-0.34" spread="0.760"/>
                    <measurement group_id="O4" value="-0.48" spread="0.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 61, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.654"/>
                    <measurement group_id="O2" value="-0.45" spread="0.812"/>
                    <measurement group_id="O3" value="-0.40" spread="0.839"/>
                    <measurement group_id="O4" value="-0.68" spread="0.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.666"/>
                    <measurement group_id="O2" value="-0.40" spread="0.874"/>
                    <measurement group_id="O3" value="-0.44" spread="0.933"/>
                    <measurement group_id="O4" value="-0.57" spread="0.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.652"/>
                    <measurement group_id="O2" value="-0.51" spread="0.769"/>
                    <measurement group_id="O3" value="-0.47" spread="0.903"/>
                    <measurement group_id="O4" value="-0.63" spread="0.784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Discomfort</title>
        <description>Participants were asked to rate their abdominal discomfort for the past 24 hours on a scale from 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
        <time_frame>Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)</time_frame>
        <population>mITT population with a value at both baseline and the last 2 weeks of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Discomfort</title>
          <description>Participants were asked to rate their abdominal discomfort for the past 24 hours on a scale from 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
          <population>mITT population with a value at both baseline and the last 2 weeks of treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.730"/>
                    <measurement group_id="O2" value="-0.51" spread="0.787"/>
                    <measurement group_id="O3" value="-0.50" spread="0.703"/>
                    <measurement group_id="O4" value="-0.42" spread="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9826</p_value>
            <method>Welchâ€™s t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5188</p_value>
            <method>Welchâ€™s t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5029</p_value>
            <method>Welchâ€™s t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Discomfort</title>
        <description>Participants were asked to rate their abdominal discomfort for the past 24 hours on a scale from 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, and 4</time_frame>
        <population>mITT population with a value at both baseline and the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Discomfort</title>
          <description>Participants were asked to rate their abdominal discomfort for the past 24 hours on a scale from 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.</description>
          <population>mITT population with a value at both baseline and the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.652"/>
                    <measurement group_id="O2" value="-0.35" spread="0.609"/>
                    <measurement group_id="O3" value="-0.24" spread="0.755"/>
                    <measurement group_id="O4" value="-0.23" spread="0.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 61, 61, 59, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.705"/>
                    <measurement group_id="O2" value="-0.48" spread="0.752"/>
                    <measurement group_id="O3" value="-0.39" spread="0.825"/>
                    <measurement group_id="O4" value="-0.49" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.741"/>
                    <measurement group_id="O2" value="-0.43" spread="0.859"/>
                    <measurement group_id="O3" value="-0.42" spread="0.884"/>
                    <measurement group_id="O4" value="-0.45" spread="1.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 61, 61, 59, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.684"/>
                    <measurement group_id="O2" value="-0.51" spread="0.787"/>
                    <measurement group_id="O3" value="-0.50" spread="0.703"/>
                    <measurement group_id="O4" value="-0.42" spread="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Global Satisfaction at End of Treatment</title>
        <description>On day 29 (or at early termination), participants were asked about their degree of satisfaction with constipation and abdominal symptoms from the start of study drug dosing to Day 28 (or early termination visit). The grades were as follows: 1, markedly worsened; 2, moderately worsened; 3, slightly worsened; 4, unchanged; 5, slightly improved; 6, moderately improved; and 7, markedly improved.</description>
        <time_frame>Day 29, or at early termination</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Global Satisfaction at End of Treatment</title>
          <description>On day 29 (or at early termination), participants were asked about their degree of satisfaction with constipation and abdominal symptoms from the start of study drug dosing to Day 28 (or early termination visit). The grades were as follows: 1, markedly worsened; 2, moderately worsened; 3, slightly worsened; 4, unchanged; 5, slightly improved; 6, moderately improved; and 7, markedly improved.</description>
          <population>mITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Markedly worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Markedly improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995</title>
        <description>Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.</description>
        <time_frame>Day 1 and Day 28 predose and 1, 2, 4, 8, and 24 hours postdose</time_frame>
        <population>The PK parameter population (PK population) includes all participants who received study drug with at least one PK parameter estimated adequately on Day 1 or Day 28</population>
        <group_list>
          <group group_id="O1">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995</title>
          <description>Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.</description>
          <population>The PK parameter population (PK population) includes all participants who received study drug with at least one PK parameter estimated adequately on Day 1 or Day 28</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naldemedine Day 1 (n = 9, 9, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.987" spread="41.1"/>
                    <measurement group_id="O2" value="1.89" spread="48.2"/>
                    <measurement group_id="O3" value="3.67" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naldemedine Day 28 (n = 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="25.8"/>
                    <measurement group_id="O2" value="2.00" spread="22.7"/>
                    <measurement group_id="O3" value="4.03" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995 Day 1 (n = 9, 9, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not calculable as plasma concentrations of Nor-S-297995 on Day 1 were below the limit of quantification.</measurement>
                    <measurement group_id="O2" value="0.107" spread="7.8"/>
                    <measurement group_id="O3" value="0.184" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995 Day 28 (n = 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.111" spread="27.1"/>
                    <measurement group_id="O2" value="0.148" spread="59.9"/>
                    <measurement group_id="O3" value="0.218" spread="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration (Tmax) of Naldemedine and Metabolite Nor-S-297995</title>
        <description>Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.</description>
        <time_frame>Day 1 and Day 28 predose and 1, 2 , 4, 8, and 24 hours postdose</time_frame>
        <population>PK population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of Naldemedine and Metabolite Nor-S-297995</title>
          <description>Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.</description>
          <population>PK population with available data</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naldemedine Day 1 (n = 9, 9, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.97" upper_limit="2.27"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.97" upper_limit="4.02"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.95" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naldemedine Day 28 (n = 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="1.00" upper_limit="1.97"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.03"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995 Day 1 (n = 9, 5, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not calculable as plasma concentrations of Nor-S-297995 on Day 1 were below the limit of quantification.</measurement>
                    <measurement group_id="O2" value="4.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="4.03" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995 Day 28 (n = 3, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.97" upper_limit="8.03"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Hour 0 to the Time Point of the Last Measurable Concentration Within the Dose Interval (AUC0-Ï„)</title>
        <description>Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.</description>
        <time_frame>Day 1 and Day 28 predose and 1, 2 , 4, 8, and 24 hours postdose</time_frame>
        <population>PK population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Hour 0 to the Time Point of the Last Measurable Concentration Within the Dose Interval (AUC0-Ï„)</title>
          <description>Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.</description>
          <population>PK population with available data</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naldemedine Day 1 (n = 6, 8, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.491" spread="24.5"/>
                    <measurement group_id="O2" value="15.95" spread="42.6"/>
                    <measurement group_id="O3" value="30.58" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naldemedine Day 28 (n = 3, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.677" spread="33.7"/>
                    <measurement group_id="O2" value="16.94" spread="46.6"/>
                    <measurement group_id="O3" value="31.72" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995 Day 1 (n = 9, 8, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not calculable as plasma concentrations of Nor-S-297995 on Day 1 were below the limit of quantification.</measurement>
                    <measurement group_id="O2" value="0.5106" spread="55.5"/>
                    <measurement group_id="O3" value="2.950" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nor-S-297995 Day 28 (n = 3, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3522" spread="896.9"/>
                    <measurement group_id="O2" value="0.8158" spread="463.1"/>
                    <measurement group_id="O3" value="2.256" spread="140.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Treatment-emergent adverse events (TEAEs) were adverse events that occurred after the first dose of study drug.
Treatment-related TEAEs were defined as TEAEs that were considered by the Investigator to be definitely, probably, or possibly related to study drug.</description>
        <time_frame>From first dose of study drug through 28 days after the last dose of study treatment (up to 57 days).</time_frame>
        <population>Adverse events were assessed using the safety population. The safety population included all participants who received study drug. This population was analyzed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo orally once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Naldemedine 0.1 mg</title>
            <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Naldemedine 0.2 mg</title>
            <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Naldemedine 0.4 mg</title>
            <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Treatment-emergent adverse events (TEAEs) were adverse events that occurred after the first dose of study drug.
Treatment-related TEAEs were defined as TEAEs that were considered by the Investigator to be definitely, probably, or possibly related to study drug.</description>
          <population>Adverse events were assessed using the safety population. The safety population included all participants who received study drug. This population was analyzed as treated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug through 28 days after the last dose of study treatment (up to 57 days).</time_frame>
      <desc>The safety population included all participants who received study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo orally once daily for 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Naldemedine 0.1 mg</title>
          <description>Participants received 0.1 mg naldemedine orally once daily for 28 days.</description>
        </group>
        <group group_id="E3">
          <title>Naldemedine 0.2 mg</title>
          <description>Participants received 0.2 mg naldemedine orally once daily for 28 days.</description>
        </group>
        <group group_id="E4">
          <title>Naldemedine 0.4 mg</title>
          <description>Participants received 0.4 mg naldemedine orally once daily for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707</phone>
      <email>shionogiclintrials-admin@shionogi.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

